Donald Emil Ganem
Director Ejecutivo en Via Nova Therapeutics, Inc. .
Perfil
Donald Emil Ganem currently works in Via Nova Therapeutics, Inc. as the President, Chief Executive Officer & Director.
Cargos activos de Donald Emil Ganem
Empresas | Cargo | Inicio |
---|---|---|
Via Nova Therapeutics, Inc.
Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Director Ejecutivo | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Via Nova Therapeutics, Inc.
Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Health Technology |
- Bolsa de valores
- Insiders
- Donald Emil Ganem